Akeso, Inc. (AKESF)

Market Cap	14.87B +79.0%
Revenue (ttm)	436.96M +43.9%
Net Income	-159.13M
EPS	-0.18
Shares Out	n/a
PE Ratio	n/a
Forward PE	107.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,400
Average Volume	1,821
Open	15.48
Previous Close	15.50
Day's Range	15.00 - 15.48
52-Week Range	8.25 - 23.15
Beta	0.28
RSI	58.32
Earnings Date	Mar 26, 2026

About Akeso

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat my...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 3,761
• Stock Exchange: OTCMKTS
• Ticker Symbol: AKESF

Financial Performance

In 2025, Akeso's revenue was 3.06 billion, an increase of 43.90% compared to the previous year's 2.12 billion. Losses were -1.11 billion, 116.3% more than in 2024.

Financial numbers in CNY